Get the Stockscreener App
98.60
0.09%
-0.09
After Hours:
98.60
Amedisys Inc stock is traded at $98.60, with a volume of 507.43K.
It is down -0.09% in the last 24 hours and up +0.21% over the past month.
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
See More
Previous Close:
$98.69
Open:
$98.13
24h Volume:
507.43K
Relative Volume:
1.25
Market Cap:
$3.24B
Revenue:
$2.32B
Net Income/Loss:
$82.93M
P/E Ratio:
39.13
EPS:
2.52
Net Cash Flow:
$203.54M
1W Performance:
+0.79%
1M Performance:
+0.21%
6M Performance:
+6.59%
1Y Performance:
+0.56%
1-Day Range:
$98.13
$99.00
1-Week Range:
$96.72
$99.00
52-Week Range:
$82.15
$99.00
Amedisys Inc Stock (AMED) Company Profile
Name
Amedisys Inc
Sector
Industry
Phone
(225) 292-2031
Address
3854 AMERICAN WAY, BATON ROUGE, LA
Compare AMED with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMED
Amedisys Inc
|
98.60 | 3.20B | 2.32B | 82.93M | 203.54M | 2.52 |
|
HCA
Hca Healthcare Inc
|
353.99 | 82.88B | 72.70B | 5.97B | 7.29B | 23.79 |
|
THC
Tenet Healthcare Corp
|
161.28 | 14.50B | 20.52B | 1.46B | 1.41B | 15.12 |
|
FMS
Fresenius Medical Care Ag Adr
|
25.34 | 15.35B | 20.92B | 666.06M | 1.85B | 1.1422 |
|
EHC
Encompass Health Corp
|
110.13 | 10.91B | 5.51B | 494.70M | 386.40M | 4.84 |
|
DVA
Davita Inc
|
140.36 | 11.03B | 12.82B | 936.34M | 1.47B | 10.74 |
Amedisys Inc Stock (AMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-07-23 | Downgrade | Truist | Buy → Hold |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Neutral |
| Mar-13-23 | Initiated | Barclays | Equal Weight |
| Oct-27-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-02-22 | Downgrade | UBS | Neutral → Sell |
| Jun-29-22 | Initiated | Stifel | Hold |
| Jun-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-01-22 | Upgrade | UBS | Sell → Neutral |
| Feb-25-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-25-22 | Reiterated | Credit Suisse | Outperform |
| Feb-25-22 | Reiterated | Oppenheimer | Outperform |
| Feb-25-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-25-22 | Reiterated | Raymond James | Outperform |
| Feb-25-22 | Reiterated | Truist | Buy |
| Sep-27-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | UBS | Sell |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Aug-10-21 | Reiterated | The Benchmark Company | Buy |
| Aug-05-21 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-20-20 | Resumed | Barclays | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Buy |
| Jun-18-20 | Upgrade | The Benchmark Company | Hold → Buy |
| May-07-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-09-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-17-20 | Initiated | Credit Suisse | Outperform |
| Nov-01-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-22-19 | Resumed | Stephens | Equal-Weight |
| Sep-17-19 | Initiated | Deutsche Bank | Buy |
| May-02-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-14-18 | Initiated | Barclays | Equal Weight |
| Nov-16-18 | Initiated | UBS | Neutral |
| Oct-30-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-03-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-19-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-09-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Nov-08-17 | Reiterated | Mizuho | Buy |
| Nov-02-17 | Upgrade | The Benchmark Company | Hold → Buy |
| Aug-21-17 | Initiated | BofA/Merrill | Neutral |
View All
Amedisys Inc Stock (AMED) Latest News
What is the dividend policy of Amedisys Inc. stockLow Risk Watchlist With High Returns - jammulinksnews.com
Amedisys (AMED) Q2 Revenue Tops 5% - The Motley Fool
Amedisys stock hits 52-week high at 98.63 USD - Investing.com Australia
Amedisys stock hits 52-week high at 98.63 USD By Investing.com - Investing.com South Africa
Amedisys Sees Hospice Revenue Rise Amid DOJ’s UnitedHealth Group Acquisition Lawsuit - Hospice News
AMEDISYS INC SEC 10-Q Report - TradingView
Amedisys Inc. Volume Confirms Breakout — Analysts BullishAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Amedisys 2025 Q2 Earnings Record High Net Income Despite Decline - AInvest
Amedisys: Q2 Earnings Snapshot - Norwalk Hour
Amedisys (AMED) Q2 2025 Earnings: Resilience Amid Merger Costs and Industry Consolidation - AInvest
Amedisys (AMED) Q2 Earnings Beat: A Strategic Buy Opportunity Amid Merger Uncertainty? - AInvest
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings - Nasdaq
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Amedisys Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Amedisys earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Amedisys Outpaces Expectations With Strong Q2 Results - Finimize
Amedisys Reports Q2 2025 Financial Results Amid Merger - TipRanks
Amedisys Reports Second Quarter 2025 Financial Results - The Globe and Mail
Amedisys Reports Retreat In Q2 Profit - Nasdaq
Amedisys, Inc. Reports Q2 2025 Financial Results with Increased Revenue Despite Merger-Related Expenses - Quiver Quantitative
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 29, 2025 in Petco Health and Wellness Company, Inc. LawsuitWOOF - The Globe and Mail
Amedisys Inc. Stock Poised for Technical ComebackRisk Managed Intraday Trade Alerts Increase in Volume - metal.it
How Amedisys Inc. stock performs during market volatilityAI Trading Suggestions With Accuracy Focus Released - metal.it
What are analysts’ price targets for Amedisys Inc. in the next 12 monthsSwing Trade Forecasts For Smart Trading - jammulinksnews.com
Will Amedisys Inc. stock benefit from interest rate changesTriple Digit Growth Focused Trade Plan Reviewed - metal.it
What institutional investors are buying Amedisys Inc. stockAchieve rapid financial growth with expert help - jammulinksnews.com
When is Amedisys Inc. stock expected to show significant growthFree Consultation - jammulinksnews.com
What makes Amedisys Inc. stock price move sharplyInvest smarter and grow your wealth faster - jammulinksnews.com
What is the risk reward ratio of investing in Amedisys Inc. stockOutstanding risk-reward balance - jammulinksnews.com
What catalysts could drive Amedisys Inc. stock higher in 2025Get expert analysis on top stock picks - jammulinksnews.com
Should I hold or sell Amedisys Inc. stock in 2025Superior stock selection - jammulinksnews.com
What are the latest earnings results for Amedisys Inc.Phenomenal capital gains - jammulinksnews.com
How strong is Amedisys Inc. company’s balance sheetBuild a portfolio that outperforms the market - jammulinksnews.com
Does Amedisys Inc. stock perform well during market downturnsUnlock powerful market analysis and alerts - jammulinksnews.com
What analysts say about Amedisys Inc. stock outlookConsistently high yield - jammulinksnews.com
What analysts say about Amedisys Inc. stockUnstoppable trading performance - Autocar Professional
What drives Amedisys Inc. stock priceHigh-impact stock picks - PrintWeekIndia
Can Amedisys Inc. stock recover from recent declineHigh-velocity gains - jammulinksnews.com
Is Amedisys Inc. a good long term investmentBreakneck growth rates - jammulinksnews.com
Amedisys Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Amedisys Inc Stock (AMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.21%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):